Published 1 day ago • loading... • Updated 1 day ago

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

The leading independent proxy advisory firm has advised Dynavax shareholders to support all four director candidates at the upcoming Annual Meeting scheduled for June 11, 2025, in Emeryville, California.
ISS based its recommendation on Dynavax's well-reasoned strategy led by an experienced leadership team and highlighted that the opposing group Deep Track did not offer sufficient justification for altering the current approach.
Dynavax, a commercial-stage biopharmaceutical company, develops vaccines using CpG 1018, with four programs in development and over 15 partnerships advancing clinical and preclinical work.
The company has delivered 203% total return over five years and generated over $950 million from COVID-19 vaccine adjuvant business, while leading in the U.S. Hepatitis B vaccine market.
Dynavax urged stockholders to vote on the GOLD proxy card for all nominees, stating that replacing any director with Deep Track's nominees would reduce vital expertise and harm long-term stockholder value.

Insights by Ground AI

Does this summary seem wrong?